Presentations

Ensuring copay assistance counts for patients: A federal update

Ensuring copay assistance counts for patients: A federal update

Carl Schmid discusses on a National Consumers League webinar current federal advocacy efforts to ensure that copay assistance for prescription drugs counts. This includes comments on two regulations, a congressional bill, and recent litigation initiated by HIV+Hep and two diabetes groups.

read more

Press briefing on HIV+Hep, DLC, and DPAC vs. HHS

The HIV+Hepatitis Policy Insite, the Diabetes Leadership Council, and the Diabetes Patient Advocacy Coalition filed suit in the U.S. District Court for the District of Columbia challenging a federal rule that allows health insurers and pharmacy benefits managers to avoid counting drug manufacturer copay assistance toward patients’ out-of-pocket cost obligations. Due to increased deductibles and cost-sharing requirements, patients rely on copay assistance to help them afford their medications.

read more
Understanding the Benefits of Multiple Options for PrEP Therapy

Understanding the Benefits of Multiple Options for PrEP Therapy

Carl Schmid: It’s important to have different types of PrEP. Up until now, it’s been a daily pill, which may be sufficient for some people, but people may not want to take a pill for a disease that they don’t have. People may forget taking a pill every day. They may not adhere to the prescribed course. It is important to have long-acting medications, and people don’t have to think about taking a drug every day. It could help with adherence, and the studies show that it’s superior. What is it all about? What is the purpose of PrEP to prevent HIV? These FDA studies show that the long-acting [PrEP] is superior. There are fewer infections.

read more

Pin It on Pinterest